R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - rProtein (27)

Modality Indication Targets Stage Company Project No. Detail
1 Lead Discovery: Dual-Mechanism Protein Therapy for Inflammatory Control and 'Cold-to-Hot' Tumor Conversion
rProtein CRC(colorectal Cancer) **** Lead Korea Research Institute of Bioscience and Biotechnology(KRIBB) RS-2026-25503253
2 Preclinical Discovery of Pearl-101, a First-in-Class Poly(ADP-ribose)-Stabilizing Peptide Therapeutic for BRCA-Mutant Therapy-Resistant Breast Cancer
rProtein Breast Cancer Poly(ADP-ribose) Candidate Pearlsinmires Co., Ltd. RS-2026-25503204
3 Advancing in vivo CAR technology based on recombinant proteins for the treatment of CD19 B-cell blood cancers
rProtein CD19 positive B cell blood cancer CD19 Lead Kangwon National University RS-2026-25503120
4 Development of a Solid Tumor Therapeutic Candidate Using a T-SphaeraTM-PD-L1 x VEGF Multi-specific Therapeutics (TSMT-01)
rProtein Solid Tumors (NSCLC, TNBC, etc.) PD-L1 and VEGF (multivalency, high avidity) Candidate CELLemedy Inc. RS-2026-25502818
5 Development of an AI-Based PD1-IL18v Bispecifc candidate with immune cell-specific activity in the tumor microenvironment.
rProtein Patients with primary or acquired resistance to PD-1 inhibitors PD-1, IL-18 Candidate Galux Inc. RS-2026-25501722
6 Development of innovative anti-cancer treatment through tumor microenvironment-specific targeting
rProtein Solid tumors TGF-β and *** Preclinical MedPacto, Inc. RS-2025-25449690
7 Development of New Generation HPV Therapeutic Vaccine: Through Dual Targeting of Dendritic Cell TLR5/NLRC4 Pathways
rProtein High-risk HPV infection–induced cervical intraepithelial neoplasia (CIN) and early-stage cervical ca Dendritic cells (CD11c⁺ DCs) via dual activation of TLR5/NLRC4 pathways using HPV16/18/52/58/33/45 E Lead Chonnam National University R&BD Foundation RS-2025-25446859
8 Establishing the Foundation for Nonclinical Entry of VLP-Peptide-Based Pancreatic Cancer Immunotherapy Vaccine Candidate
rProtein Pancreatic Cancer and Prevention of Its Metastasis hTERT Candidate POSVAX Co., LTD. RS-2025-25444576
9 Development of EGFR-targeting ADC candidate for the treatment of metastatic (late-stage) colorectal cancer
rProtein Colon cancer EGFR Candidate ProEn Therapeutics Inc. RS-2025-02223464
10 Development of a First-in-Class αPD-1/αVEGF/IL-2v Triple-Action Immuno-Oncology Therapeutic for Refractory Solid Tumors
rProtein Solid cancer αPD-1/αVEGF/IL-2v Lead MustBio RS-2025-02172980
11
rProtein Metastatic Melanoma CTLA-4/PD-L1, IL-2R Phase 1 GI Innovation RS-2024-00459844
12 Development of peptide vaccine against the glioblastoma with CMV pp65
rProtein GBM Glioblastoma, multifocal N/A Preclinical NA Vaccine Institute RS-2024-00337146
13 Efficacy and safety evaluation of the peptide candidate CBT-001-839 for CAIX-targeted cancer diagnostic and therapeutic radiopharmaceuticals
rProtein ccRCC CAIX Candidate C-BIOMEX RS-2023-00218641
14 Development of Immunoferritin Cellem001 with Dual Immune Checkpoints Blockade and T/NK-tumor Cell Engager
rProtein NSCLC, Melanoma PD-L1, TIGIT Preclinical Cellemedy RS-2023-00218402
15 Development of next-generation cancer immunotherapy via FAP-targeted IL-12 attenuation-based TMEkineTM
rProtein Solid Tumor FAP, IL-12 Candidate KANAPH Therapeutics RS-2022-00166851
16 Non-clinical study and IND approval of GI-108, a metabolic immune anti-cancer drug
rProtein Solid Tumor CD73, IL-2 Preclinical GI Innovation, Inc RS-2022-00166700
17 Development of HER2-positive cancer treatment candidate through interferon-beta immunocytokine efficacy evaluation and production process research
rProtein HER2+ tumor IFN-β Candidate Genopharm Inc. RS-2022-00166539
18 Derivation of lead substance for colorectal cancer treatment of Repebody-drug conjugate with EGFR overexpression tumor-specific selective effect
rProtein Solid Tumor (EGFR overexpression) EGFR Lead ProEn Therapeutics RS-2022-00166310
19 Development of personalized cancer vaccine against advanced stage lung cancer patients with immunotherapy resistance
rProtein Lung cancer Tumor specific neoantigens predicted from deep learning platform technology Candidate Penta Medix RS-2022-00166187
20 Non-clinical development of long-acting IL-2 analog (HM16390) with optimized IL-2 receptor binding property
rProtein Renal cell carcinoma, melanoma IL-2 Preclinical Hanmi Pharm. Co., Ltd. RS-2022-00165557
21 Development of macrophage-targeted clodronate-glycosylated albumin complex 
to inhibit tumor growth
rProtein Malignant tumor Macrophage Hit Seoul National University HN22C0644
22 Development of tumor-derived exosome rupture peptide for combinational immunotherapy of colorectal cancer
rProtein Colorectal cancer Phopholipid layer Hit Sungkyunkwan University HN22C0624
23 Development of a treatment for refractory solid tumor targeting activated stellate cells
rProtein Solid tumor retinoid Lead Senelix HN22C0554
24 A Phase 1/2, open-label, dose-escalation, and expansion study to evaluate safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101 as a single agent and in combination with pembrolizumab, lenvatinib or local radiotherapy in patients with advanced or metastatic solid tumors (Keynote B59)
rProtein Advanced or Metastatic Solid Tumor CD80, IL-2 Phase 1 GI Innovation, Inc. HN22C0451
25 Development of peptide vaccine against the pancreatic or lung cancers with KRAS mutation
rProtein Pancreatic cancer, Lung cancer KRAS mutant Candidate NA Vaccine Institute HN21C1308
26 Development of ‘Best-in-Class’ IL-2 for Solid Tumor Treatments
rProtein Kidney cancer, Skin cancer IL-2 Hit Genuv HN21C1125
27 Efficacy and safety on anti-cancer drug candidate of immune-checkpoint protein and cytokine fused platform
rProtein Cancer IL-21, PD-1 Lead BIOnSYSTEMS HN21C1099
BACK